- Home
- ELLO vs CKPT Comparison
ELLO vs CKPT Comparison
Compare ELLO & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- CKPT
- Stock Information
- Founded
- ELLO 1987
- CKPT 2014
- Country
- ELLO Israel
- CKPT United States
- Employees
- ELLO N/A
- CKPT N/A
- Industry
- ELLO Electric Utilities: Central
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- CKPT Health Care
- Exchange
- ELLO Nasdaq
- CKPT Nasdaq
- Market Cap
- ELLO 208.2M
- CKPT 172.4M
- IPO Year
- ELLO 1995
- CKPT 2017
- Fundamental
- Price
- ELLO N/A
- CKPT $4.01
- Analyst Decision
- ELLO
- CKPT Buy
- Analyst Count
- ELLO 0
- CKPT 3
- Target Price
- ELLO N/A
- CKPT $4.33
- AVG Volume (30 Days)
- ELLO 5.2K
- CKPT 5.8M
- Earning Date
- ELLO 04-15-2025
- CKPT 03-28-2025
- Dividend Yield
- ELLO N/A
- CKPT N/A
- EPS Growth
- ELLO N/A
- CKPT N/A
- EPS
- ELLO N/A
- CKPT N/A
- Revenue
- ELLO $41,895,641.00
- CKPT $41,000.00
- Revenue This Year
- ELLO N/A
- CKPT $102,182.93
- Revenue Next Year
- ELLO N/A
- CKPT $351.71
- P/E Ratio
- ELLO N/A
- CKPT N/A
- Revenue Growth
- ELLO N/A
- CKPT N/A
- 52 Week Low
- ELLO $11.08
- CKPT $1.38
- 52 Week High
- ELLO $20.81
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- ELLO 39.48
- CKPT 65.90
- Support Level
- ELLO $14.69
- CKPT $4.01
- Resistance Level
- ELLO $15.29
- CKPT $4.06
- Average True Range (ATR)
- ELLO 0.43
- CKPT 0.03
- MACD
- ELLO -0.10
- CKPT -0.02
- Stochastic Oscillator
- ELLO 2.78
- CKPT 70.00
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.